In-silico analysis of Human miRNAs in SARS-CoV-2 Genome

Background: In Dec. 2019, a new virus (Coronavirus) was discovered in Wuhan city (China), indicating its potential for rapid fatal outbreaks in confined and cross borders areas. Statistics showed the fatality rate as about 1.4 %. Till now, there is no successful therapy for SARS-CoV-2. Method: The miRNAs from genome (Coronavirus/SARS-CoV-2) were analyzed using various computational approaches in this study. The complete genome sequence was retrieved from NCBI.   Results: We investigated potential antiviral treatment for the SARS-CoV-2 virus using host miRNAs, which could slow down the expression of viral genes to suppress viral replication. The result of our study highlighted that   hsa-miR-3675-3p (MD19), hsa-miR-363-5p (MD220), hsa-miR-325 (MD306), hsa-miR-2114-5p (MD306), hsa-miR-744-3p (MR186) and hsa-miR-448 (MR186), can be used as anti-viral treatment to quell the replication of SARS-CoV-2 virus in human. Conclusion:  The findings and observations of our study opened new possibilities to explore both the pathogenesis function of miRNA and in the development of novel antiviral drugs.